50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   271.59 (-2.98%)
AAPL   142.57 (-4.85%)
MSFT   235.78 (-2.19%)
META   137.42 (-2.96%)
GOOGL   96.55 (-3.50%)
AMZN   114.82 (-2.70%)
TSLA   270.29 (-6.09%)
NVDA   121.57 (-4.55%)
NIO   15.56 (-10.21%)
BABA   78.51 (-3.06%)
AMD   64.17 (-6.13%)
T   15.53 (-1.90%)
MU   50.00 (-1.96%)
CGC   2.83 (-6.91%)
F   11.51 (-5.50%)
GE   62.41 (-3.18%)
DIS   97.41 (-2.00%)
AMC   7.17 (-6.52%)
PYPL   89.38 (-1.91%)
PFE   44.36 (-0.16%)
NFLX   241.09 (-1.68%)
QQQ   271.59 (-2.98%)
AAPL   142.57 (-4.85%)
MSFT   235.78 (-2.19%)
META   137.42 (-2.96%)
GOOGL   96.55 (-3.50%)
AMZN   114.82 (-2.70%)
TSLA   270.29 (-6.09%)
NVDA   121.57 (-4.55%)
NIO   15.56 (-10.21%)
BABA   78.51 (-3.06%)
AMD   64.17 (-6.13%)
T   15.53 (-1.90%)
MU   50.00 (-1.96%)
CGC   2.83 (-6.91%)
F   11.51 (-5.50%)
GE   62.41 (-3.18%)
DIS   97.41 (-2.00%)
AMC   7.17 (-6.52%)
PYPL   89.38 (-1.91%)
PFE   44.36 (-0.16%)
NFLX   241.09 (-1.68%)
QQQ   271.59 (-2.98%)
AAPL   142.57 (-4.85%)
MSFT   235.78 (-2.19%)
META   137.42 (-2.96%)
GOOGL   96.55 (-3.50%)
AMZN   114.82 (-2.70%)
TSLA   270.29 (-6.09%)
NVDA   121.57 (-4.55%)
NIO   15.56 (-10.21%)
BABA   78.51 (-3.06%)
AMD   64.17 (-6.13%)
T   15.53 (-1.90%)
MU   50.00 (-1.96%)
CGC   2.83 (-6.91%)
F   11.51 (-5.50%)
GE   62.41 (-3.18%)
DIS   97.41 (-2.00%)
AMC   7.17 (-6.52%)
PYPL   89.38 (-1.91%)
PFE   44.36 (-0.16%)
NFLX   241.09 (-1.68%)
QQQ   271.59 (-2.98%)
AAPL   142.57 (-4.85%)
MSFT   235.78 (-2.19%)
META   137.42 (-2.96%)
GOOGL   96.55 (-3.50%)
AMZN   114.82 (-2.70%)
TSLA   270.29 (-6.09%)
NVDA   121.57 (-4.55%)
NIO   15.56 (-10.21%)
BABA   78.51 (-3.06%)
AMD   64.17 (-6.13%)
T   15.53 (-1.90%)
MU   50.00 (-1.96%)
CGC   2.83 (-6.91%)
F   11.51 (-5.50%)
GE   62.41 (-3.18%)
DIS   97.41 (-2.00%)
AMC   7.17 (-6.52%)
PYPL   89.38 (-1.91%)
PFE   44.36 (-0.16%)
NFLX   241.09 (-1.68%)
NASDAQ:AGRX

Agile Therapeutics - AGRX Stock Forecast, Price & News

$0.29
0.00 (-0.07%)
(As of 09/29/2022 12:21 PM ET)
Add
Compare
Today's Range
$0.29
$0.30
50-Day Range
$0.28
$0.68
52-Week Range
$0.26
$41.20
Volume
2,475 shs
Average Volume
1.41 million shs
Market Capitalization
$11.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$100.00

Agile Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
34,418.5% Upside
$100.00 Price Target
Short Interest
Healthy
3.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
1.24mentions of Agile Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$22,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.15) to ($0.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.66 out of 5 stars

Medical Sector

105th out of 1,096 stocks

Pharmaceutical Preparations Industry

33rd out of 548 stocks

AGRX stock logo

About Agile Therapeutics (NASDAQ:AGRX) Stock

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGRX Stock News Headlines

Dow Surges 200 Points; Agile Therapeutics Shares Slide
XERS, AGRX and LHDX among mid-day movers
See More Headlines
Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGRX Company Calendar

Last Earnings
8/11/2022
Today
9/29/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGRX
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$100.00
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$100.00
Forecasted Upside/Downside
+34,053.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-74,890,000.00
Net Margins
-958.70%
Pretax Margin
-1,028.59%

Debt

Sales & Book Value

Annual Sales
$4.10 million
Book Value
$3.05 per share

Miscellaneous

Free Float
37,189,000
Market Cap
$11.43 million
Optionable
Optionable
Beta
1.25

Key Executives

  • Mr. Alfred F. AltomariMr. Alfred F. Altomari (Age 63)
    Chairman & CEO
    Comp: $804.82k
  • Mr. Geoffrey P. Gilmore (Age 56)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $555.21k
  • Dr. Paul Korner M.B.A. (Age 56)
    M.D., Sr. VP & Chief Medical Officer
    Comp: $574.59k
  • Mr. Jason Butch
    Principal Financial Officer, VP & Chief Accounting Officer
  • Matthew Riley
    Head of Investor Relations & Corp. Communications
  • Ms. Amy Welsh
    VP of Marketing
  • Mr. Robert G. Conway M.E. (Age 65)
    Sr. VP & Chief Supply Chain Officer
  • Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D. (Age 54)
    M.P.H., Consultant
  • Joseph D'Urso
    Controller
  • Dr. Kathryn MacFarlane Pharm.D. (Age 56)
    Advisor













AGRX Stock - Frequently Asked Questions

Should I buy or sell Agile Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings
or view top-rated stocks.

What is Agile Therapeutics' stock price forecast for 2022?

2 analysts have issued 1 year target prices for Agile Therapeutics' shares. Their AGRX share price forecasts range from $100.00 to $100.00. On average, they expect the company's stock price to reach $100.00 in the next twelve months. This suggests a possible upside of 34,029.7% from the stock's current price.
View analysts price targets for AGRX
or view top-rated stocks among Wall Street analysts.

How have AGRX shares performed in 2022?

Agile Therapeutics' stock was trading at $19.5240 at the beginning of the year. Since then, AGRX shares have decreased by 98.5% and is now trading at $0.2930.
View the best growth stocks for 2022 here
.

When is Agile Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our AGRX earnings forecast
.

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) announced its quarterly earnings data on Thursday, August, 11th. The specialty pharmaceutical company reported ($2.71) EPS for the quarter. The specialty pharmaceutical company had revenue of $2.13 million for the quarter, compared to analysts' expectations of $2.13 million. Agile Therapeutics had a negative trailing twelve-month return on equity of 1,016.70% and a negative net margin of 958.70%. During the same period last year, the firm posted ($8.00) earnings per share.

When did Agile Therapeutics' stock split?

Agile Therapeutics's stock reverse split on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

How do I buy shares of Agile Therapeutics?

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agile Therapeutics' stock price today?

One share of AGRX stock can currently be purchased for approximately $0.29.

How much money does Agile Therapeutics make?

Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $11.43 million and generates $4.10 million in revenue each year. The specialty pharmaceutical company earns $-74,890,000.00 in net income (profit) each year or ($21.69) on an earnings per share basis.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com.

This page (NASDAQ:AGRX) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.